In our collaboration with Matrix45 USA, we could estimate the savings on Medicare’s bill for the coverage of Toripalimab in metastatic nasopharyngeal carcinoma that was associated with 90% accumulative probability

We are proud to be part of this assessment for the net monetary value of Toripalimab in the US market

Check out: www.tandfonline.com